뉴스벤징가
Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing Deal
· 발표
기사 요약
Glaukos reports positive three-year Epioxa study results and secures an exclusive license for RevOpsis retinal candidate RO-104.
기사 원문에서 발췌했어요.
댓글 —
댓글을 불러오고 있어요…